These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23614843)

  • 21. ICH topic: note for guidance on safety pharmacology studies for human pharmaceuticals.
    Olejniczak K; Bode G
    Fundam Clin Pharmacol; 2002 Apr; 16(2):79-81. PubMed ID: 12031060
    [No Abstract]   [Full Text] [Related]  

  • 22. Medical schools found to vary in their drug-testing standards.
    Dean C
    N Y Times Web; 2005 May; ():A24. PubMed ID: 15981393
    [No Abstract]   [Full Text] [Related]  

  • 23. Financing new drug development in ophthalmology.
    Novack GD
    J Glaucoma; 2000 Apr; 9(2):195-9. PubMed ID: 10782633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From a constitutional right to a policy of exceptions: Abigail Alliance and the future of access to experimental therapy.
    Shah S; Zettler P
    Yale J Health Policy Law Ethics; 2010; 10(1):135-96. PubMed ID: 20229846
    [No Abstract]   [Full Text] [Related]  

  • 25. Managing oncology research protocols.
    Lunik MC
    Top Hosp Pharm Manage; 1994 Jul; 14(2):11-21. PubMed ID: 10136201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agency criticises drug trial.
    Day M
    BMJ; 2006 Jun; 332(7553):1290. PubMed ID: 16740539
    [No Abstract]   [Full Text] [Related]  

  • 27. Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-averse environment.
    Walker S; McAuslane N; Liberti L; Salek S
    Clin Pharmacol Ther; 2009 Mar; 85(3):241-6. PubMed ID: 19223879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What's so great about newness?
    Light DW
    Health Aff (Millwood); 2007; 26(6):1793; author reply 1793-4. PubMed ID: 17978409
    [No Abstract]   [Full Text] [Related]  

  • 29. Experience with validation of clinical trial materials: an inspector's viewpoint.
    Wolfe L
    Dev Biol (Basel); 2003; 113():27-33. PubMed ID: 14620849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How some patients in new-drug trials can get cut off.
    Anand G
    Wall St J (East Ed); 2003 Dec; ():A1, A11. PubMed ID: 14971381
    [No Abstract]   [Full Text] [Related]  

  • 31. Tighter safety controls needed over clinical trials, says FDA.
    Am J Health Syst Pharm; 1995 Feb; 52(4):357. PubMed ID: 7757854
    [No Abstract]   [Full Text] [Related]  

  • 32. Patient group seeks overhaul of FDA clinical trial system in court.
    Hede K
    J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
    [No Abstract]   [Full Text] [Related]  

  • 33. Post-marketing surveillance in Japan: Potential best way forward.
    Hiroi S; Kubota K; Mishiro I; Fernandez JL
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1138-1139. PubMed ID: 28913964
    [No Abstract]   [Full Text] [Related]  

  • 34. End points for cardiovascular drug trials in pediatric patients.
    Sinaiko AR; Lauer RM; Sanders SP
    Am Heart J; 2001 Aug; 142(2):229-32. PubMed ID: 11479459
    [No Abstract]   [Full Text] [Related]  

  • 35. [New antihypertensive drugs].
    Derer W; Müller DN; Dechend R
    MMW Fortschr Med; 2012 Mar; 154(4):72-3. PubMed ID: 22619843
    [No Abstract]   [Full Text] [Related]  

  • 36. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
    Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The death of academic clinical trials.
    Morice AH
    Lancet; 2003 May; 361(9368):1568. PubMed ID: 12737908
    [No Abstract]   [Full Text] [Related]  

  • 38. Serious adverse event reporting.
    Stewart WC; Stewart JA; Demos CM; Turner M
    Ophthalmology; 2009 Dec; 116(12):2485-2485.e1. PubMed ID: 19948292
    [No Abstract]   [Full Text] [Related]  

  • 39. The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium.
    Weinreb RN; Kaufman PL
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1497-505. PubMed ID: 19321793
    [No Abstract]   [Full Text] [Related]  

  • 40. [Structured introduction of new drug therapies: valuable initiative--transparency required].
    Lundkvist J; Henriksson F
    Lakartidningen; 2009 Jan 7-13; 106(1-2):51. PubMed ID: 19235324
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.